← Eichor
Study identifier: NCT04233749 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Condition: Lichen Planus Pigmentosus · Erythema Dyschromicum Perstans · Ashy Dermatosis of Ramirez  ·  Sponsor: Henry Ford Health System

PhasePhase 2
Planned participants5
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

This description comes directly from the study's public registry record.

Talk to the study team

Angela Parks-Miller, RN  ·  1-313-916-0426  ·  amiller5@hfhs.org

Jennifer Creasor, RN  ·  1-313-916-0412  ·  jcreaso2@hfhs.org

Always discuss trial participation with your own doctor first.

Locations (1)

New Center OneDetroit, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04233749